BLRX
BioLineRx Ltd. NASDAQ Listed Jul 27, 2011$2.84
+4.65%
vs $2.71
Mkt Cap $12.3M
52w Low $2.15
28.5% of range
52w High $4.56
50d MA $3.07
200d MA $2.97
P/E (TTM)
—
EV/EBITDA
—
P/B
0.5x
Debt/Equity
0.6x
ROE
—
P/FCF
-1.4x
RSI (14)
37.00
ATR (14)
$0.17
Beta
0.48
50d MA
$3.07
200d MA
$2.97
Avg Volume
16.7K
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Modi’in Technology Park · Hevel Modi'in 7177871 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | BMO | -0.39 | -0.27 | +29.9% | 2.32 | -0.9% | +4.3% | -1.7% | -2.1% | +1.7% | -5.1% | — |
| Nov 24, 2025 | BMO | -0.41 | -0.22 | +46.3% | 3.50 | +0.0% | +1.4% | -2.8% | +0.6% | -3.7% | -4.2% | — |
| Aug 14, 2025 | BMO | -0.35 | -1.00 | -185.7% | 3.77 | -3.2% | -1.6% | +3.2% | -2.3% | -1.1% | -3.0% | — |
| May 27, 2025 | BMO | -0.84 | 1.39 | +265.5% | 3.68 | +5.2% | +3.0% | +0.0% | +38.5% | -21.9% | +2.9% | — |
| Mar 25, 2025 | BMO | -4.20 | 6.00 | +242.9% | 3.34 | -0.3% | -5.1% | +0.6% | -4.4% | -3.0% | -1.4% | — |
| Nov 25, 2024 | BMO | -0.05 | -2.80 | -5500.0% | 10.87 | +9.8% | +1.7% | +3.9% | +3.5% | -1.9% | -3.8% | — |
| Aug 15, 2024 | BMO | -0.14 | 0.40 | +385.7% | 27.13 | +1.7% | +8.9% | +7.0% | -5.6% | -0.7% | -2.7% | — |
| May 28, 2024 | BMO | -0.29 | -0.01 | +96.6% | 28.76 | -4.5% | -4.0% | +18.8% | -9.1% | -1.5% | -4.8% | — |
| Mar 26, 2024 | BMO | -0.22 | -0.15 | +31.8% | 41.20 | +5.8% | +7.8% | +0.9% | -23.2% | -3.6% | -0.2% | — |
| Nov 20, 2023 | BMO | -7.20 | -12.00 | -66.7% | 68.00 | -5.9% | -10.6% | +0.0% | -2.0% | -2.0% | -2.1% | — |
| Aug 30, 2023 | BMO | -6.40 | -12.00 | -87.5% | 55.60 | +3.6% | +25.9% | +15.4% | +21.3% | -1.2% | -10.3% | — |
| May 24, 2023 | AMC | -5.60 | -6.00 | -7.1% | 62.40 | +0.0% | -0.6% | -3.2% | +4.7% | +0.3% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.67 | $4.63 | -0.9% | -5.4% | +3.4% | -7.2% | -5.7% | +11.0% |
| May 30 | Jones Trading | Upgrade | Hold → Buy | — | $3.79 | $5.87 | +54.9% | +38.5% | -21.9% | +2.9% | +10.4% | +13.1% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.68 | $3.87 | +5.2% | +3.0% | +0.0% | +38.5% | -21.9% | +2.9% |
| Apr 2 | Jones Trading | Downgrade | Buy → Hold | — | $2.92 | $2.86 | -2.1% | +6.2% | -5.2% | -9.9% | -4.9% | -2.0% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.05 | $3.18 | +4.3% | -3.0% | -1.4% | +6.2% | -5.2% | -9.9% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.12 | $11.53 | +3.7% | -2.2% | +1.7% | +3.9% | +3.5% | -1.9% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.56 | $18.12 | +3.2% | +3.2% | -0.3% | -1.6% | +0.1% | -3.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.82 | $30.09 | +0.9% | -1.5% | -4.8% | +3.6% | -3.8% | -5.6% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.76 | $27.48 | -4.5% | -4.0% | +18.8% | -9.1% | -1.5% | -4.8% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.58 | $25.59 | +0.0% | -2.8% | +3.0% | +2.6% | +3.1% | -5.9% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.00 | $47.20 | -9.2% | -20.8% | +7.8% | +0.9% | -23.2% | -3.6% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.80 | $52.80 | +0.0% | +0.8% | +0.0% | +1.5% | -1.5% | -4.5% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.60 | $65.20 | -3.6% | +0.6% | -10.6% | +0.0% | -2.0% | -2.0% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $70.40 | $75.60 | +7.4% | +10.8% | +3.1% | +11.4% | -1.8% | -10.0% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.60 | $57.60 | +3.6% | +25.9% | +15.4% | +21.3% | -1.2% | -10.3% |
| May 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $62.40 | $62.40 | +0.0% | -0.6% | -3.2% | +4.7% | +0.3% | +2.9% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.60 | $136.80 | -0.6% | -3.2% | +5.1% | -7.7% | -4.3% | +2.3% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $144.80 | $111.83 | -22.8% | -21.0% | -4.5% | -3.7% | +0.4% | -0.8% |
| Nov 25 | JMP Securities | Maintains | Market Outperform → Outperform | — | $90.40 | $90.80 | +0.4% | -0.4% | +3.1% | -1.3% | -1.3% | +3.5% |
| Nov 25 | Maxim Group | Downgrade | Buy → Hold | — | $90.40 | $90.80 | +0.4% | -0.4% | +3.1% | -1.3% | -1.3% | +3.5% |
| Nov 25 | Maxim Group | Upgrade | Hold → Buy | — | $90.40 | $90.80 | +0.4% | -0.4% | +3.1% | -1.3% | -1.3% | +3.5% |
| Nov 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $90.40 | $90.80 | +0.4% | -0.4% | +3.1% | -1.3% | -1.3% | +3.5% |
| Aug 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $630.00 | $642.00 | +1.9% | +3.8% | +4.6% | +3.5% | +0.0% | -3.4% |
| May 18 | Maxim Group | Upgrade | Hold → Buy | — | $495.84 | $512.40 | +3.3% | +1.6% | +2.5% | +2.2% | -3.5% | +1.2% |
| Feb 13 | Rodman & Renshaw | Maintains | Buy → Buy | — | $654.00 | $690.00 | +5.5% | +8.3% | -4.7% | +5.8% | +6.7% | -0.8% |
| Aug 12 | Maxim Group | Downgrade | Buy → Hold | — | $525.84 | $504.00 | -4.2% | -3.0% | +1.4% | +3.3% | +4.2% | -0.8% |
| Mar 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $678.00 | $678.00 | +0.0% | +1.8% | -4.8% | -4.1% | +0.0% | -3.8% |
| Jun 22 | JMP Securities | Maintains | Outperform → Outperform | — | $1242.06 | $1338.00 | +7.7% | +3.9% | +7.4% | -1.7% | -3.1% | +15.9% |
| Jun 22 | JP Morgan | Maintains | Market Outperform → Outperform | — | $1242.06 | $1338.00 | +7.7% | +3.9% | +7.4% | -1.7% | -3.1% | +15.9% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 5
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bnp Paribas Financial Markets | 1,800 | $4K | Added | Mar 2026 |
| 2 | Wells Fargo & Company/mn | 1,750 | $4K | New | Mar 2026 |
| 3 | Ubs Group Ag | 529 | $1K | Reduced | Mar 2026 |
| 4 | Morgan Stanley | 200 | $554 | Reduced | Dec 2025 |
| 5 | Rockefeller Capital Management L.p. | 12 | $28 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$12.3M
Enterprise Value
-$5.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.06x
P/B
0.50x
P/S
8.31x
P/FCF
-1.36x
EV/EBITDA
—
Shares Out
4.1M
Financials (TTM)
Revenue
$1.4M
Net Income
-$8.9M
EBITDA
-$8.2M
Free Cash Flow
-$8.2M
Op Cash Flow
-$8.1M
EPS Basic
$-0.29
EPS Diluted
$-2.12
EPS Forward
$-0.55
Gross Margin
74.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$40.9M
Total Liab.
$17.6M
Total Equity
$23.3M
Cash
$20.9M
LT Debt
$4.5M
Book Value/Sh
$5.68
Debt/Equity
0.56x
Current Ratio
1.95
Quick Ratio
1.78
Returns & Growth
ROE
—
ROA
—
ROIC
-31.0%
Rev Growth YoY
-95.9%
EPS Growth YoY
-150.7%
Price Returns
2W
-3.9%
1M
-12.2%
3M
-9.0%
6M
-8.1%
12M
-27.1%
Technicals
52W High
$4.56
52W Low
$2.15
50d MA
$3.07
200d MA
$2.97
RSI (14)
37.00
ATR (14)
$0.17
Beta
0.48
Avg Volume
17K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 9:54am
· Source: financialmodelingprep.com